Tatva Chintan Pharma Chem Past Earnings Performance
Past criteria checks 1/6
Tatva Chintan Pharma Chem's earnings have been declining at an average annual rate of -20.7%, while the Chemicals industry saw earnings growing at 14.4% annually. Revenues have been declining at an average rate of 2.8% per year. Tatva Chintan Pharma Chem's return on equity is 2.4%, and it has net margins of 4.7%.
Key information
-20.7%
Earnings growth rate
-23.5%
EPS growth rate
| Chemicals Industry Growth | 17.7% |
| Revenue growth rate | -2.8% |
| Return on equity | 2.4% |
| Net Margin | 4.7% |
| Next Earnings Update | 28 Jan 2025 |
Recent past performance updates
Weak Statutory Earnings May Not Tell The Whole Story For Tatva Chintan Pharma Chem (NSE:TATVA)
May 11
Recent updates
Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Price In Tune With Revenues
Sep 26Tatva Chintan Pharma Chem (NSE:TATVA) Has Affirmed Its Dividend Of ₹2.00
Aug 29Earnings Report: Tatva Chintan Pharma Chem Limited Missed Revenue Estimates By 33%
Jul 27Weak Statutory Earnings May Not Tell The Whole Story For Tatva Chintan Pharma Chem (NSE:TATVA)
May 11Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Share Price Matching Investor Opinion
Apr 04These Analysts Just Made A Notable Downgrade To Their Tatva Chintan Pharma Chem Limited (NSE:TATVA) EPS Forecasts
Jan 26Tatva Chintan Pharma Chem Limited (NSE:TATVA) Analysts Are Reducing Their Forecasts For This Year
May 10Tatva Chintan Pharma Chem Limited Just Missed Revenue By 15%: Here's What Analysts Think Will Happen Next
Jul 28Getting In Cheap On Tatva Chintan Pharma Chem Limited (NSE:TATVA) Is Unlikely
Jun 17Investors Shouldn't Be Too Comfortable With Tatva Chintan Pharma Chem's (NSE:TATVA) Robust Earnings
May 03Are Investors Undervaluing Tatva Chintan Pharma Chem Limited (NSE:TATVA) By 45%?
Dec 06Revenue & Expenses Breakdown
How Tatva Chintan Pharma Chem makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,714 | 176 | 548 | 0 |
| 30 Jun 24 | 3,846 | 261 | 552 | 0 |
| 31 Mar 24 | 3,935 | 304 | 563 | 0 |
| 31 Dec 23 | 4,198 | 377 | 526 | 0 |
| 30 Sep 23 | 4,562 | 459 | 483 | 0 |
| 30 Jun 23 | 4,496 | 452 | 416 | 0 |
| 31 Mar 23 | 4,236 | 455 | 431 | 0 |
| 31 Dec 22 | 3,976 | 460 | 377 | 0 |
| 30 Sep 22 | 3,817 | 572 | 353 | 0 |
| 30 Jun 22 | 4,152 | 825 | 324 | 0 |
| 31 Mar 22 | 4,336 | 959 | 320 | 0 |
| 31 Dec 21 | 4,438 | 995 | 311 | 0 |
| 30 Sep 21 | 4,192 | 976 | 300 | 0 |
| 30 Jun 21 | 3,557 | 687 | 279 | 0 |
| 31 Mar 21 | 3,004 | 523 | 253 | 0 |
| 31 Mar 20 | 2,632 | 378 | 217 | 0 |
| 31 Mar 19 | 2,063 | 205 | 174 | 0 |
| 31 Mar 18 | 1,358 | 123 | 131 | 0 |
Quality Earnings: TATVA has high quality earnings.
Growing Profit Margin: TATVA's current net profit margins (4.7%) are lower than last year (10.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TATVA's earnings have declined by 20.7% per year over the past 5 years.
Accelerating Growth: TATVA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: TATVA had negative earnings growth (-61.6%) over the past year, making it difficult to compare to the Chemicals industry average (9.9%).
Return on Equity
High ROE: TATVA's Return on Equity (2.4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 13:44 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tatva Chintan Pharma Chem Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sanjesh Jain | ICICI Securities Ltd. |
| Anshuman Gupta | Investec Bank plc (UK) |
| Krishanchandra Parwani | JM Financial Institutional Securities Limited |